# HVA vs IA/DA or VA in the Treatment of ND HR-AML

> **NCT06810791** · PHASE3 · RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 876 (estimated)

## Conditions studied

- Newly Diagnosed Acute Myeloid Leukemia With High Risk

## Interventions

- **DRUG:** HVA
- **DRUG:** VA
- **DRUG:** Standard Chemotherapy

## Key facts

- **NCT ID:** NCT06810791
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 876 (ESTIMATED)
- **Last updated:** 2025-02-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06810791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06810791, "HVA vs IA/DA or VA in the Treatment of ND HR-AML". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06810791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*